Cara Therapeutics reported $7.54M in Selling and Administration Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Acadia Pharmaceuticals ACAD:US $ 89.9M 6.78M
Acelrx Pharmaceuticals ACRX:US $ 6.82M 516K
Aerie Pharmaceuticals AERI:US $ 28.15M 3.38M
Cara Therapeutics CARA:US $ 7.54M 1.78M
Chugai Pharma 4519:JP 22.03B 3.23B
Depomed DEPO:US $ 10.54M 105K
Endo International Ordinary Shares ENDP:US 180.83M 45.18M
Halozyme Therapeutics HALO:US $ 57.48M 43.64M
Horizon Pharma HZNP:US 398.22M 25.49M
JAZZ PHA JAZZ:US 325.67M 16.86M
Johnson & Johnson JNJ:US $ 6.23B 288M
Neurocrine Biosciences NBIX:US $ 182.8M 17.9M
Pacira Pharmaceuticals PCRX:US $ 65M 743K
Pain Therapeutics PTIE:US $ 2.97M 54K
Pfizer PFE:US $ 3.2B 506M
Redhill Biopharma RDHL:US 20.38M 2.81M
Revance Therapeutics RVNC:US $ 46.19M 2.21M
Supernus Pharmaceuticals SUPN:US $ 100.48M 10.02M
Teva Pharmaceutical Industries TEVA:US 849M 30M
Vanda Pharmaceuticals VNDA:US $ 33M 7.85M